FBR Capital Reiterates Outperform on Galena Biopharma (GALE) Following Phase lll Investigation
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating and $2.00 price target on Galena Biopharma (NASDAQ: GALE) following an investigation of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
